Recanalization of Xen45 gel stent implant occlusion using 10 - 0 nylon suture in refractory glaucoma: a case report.
Glaucoma
Micro-invasive glaucoma surgery
Occlusion
Postoperative complications
Recanalization
Xen gel stent
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
received:
20
02
2023
accepted:
22
08
2023
medline:
23
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
Xen Gel Stent implant is a new minimally invasive surgical treatment for glaucoma that has been proven effectiveness and safety profile. However, it may also lead to some complications. Xen Gel Stent occlusion is a relatively rare complication reported less frequently and has limited treatment experience. In our case report, we proposed a novel surgical treatment using a 10 - 0 nylon suture to successfully recanalize the occluded Xen45 Gel Stent. A 16-year-old female patient had bilateral juvenile glaucoma for the past 5 years. Her right eye had undergone three glaucoma surgeries but failed. At a presentation to our hospital, the right eye's intraocular pressure (IOP) was 30 mmHg despite applying four different active principles. Xen45 Gel Stent implant was chosen for treatment, but six days after implantation, the IOP rose to 40 mmHg as a result of an anterior chamber tip occlusion of the Xen45 Gel Stent. Nd: YAG laser shockwave therapy was attempted but failed. The patient eventually had to return to the operating room for a revision procedure. The Xen45 Gel Stent was recanalized from the ab externo by making an L-shaped conjunctival incision at the fornix base and threading a 10 - 0 nylon suture through it. The IOP was successfully controlled in the 11-month follow-up without medication. If postoperative occlusion arises after Xen45 Gel Stent implantation, surgery using 10 - 0 nylon suture to recanalize Xen45 Gel Stent should be considered as a relatively safe, effective that does not require removal of Xen45 Gel Stent.
Sections du résumé
BACKGROUND
BACKGROUND
Xen Gel Stent implant is a new minimally invasive surgical treatment for glaucoma that has been proven effectiveness and safety profile. However, it may also lead to some complications. Xen Gel Stent occlusion is a relatively rare complication reported less frequently and has limited treatment experience. In our case report, we proposed a novel surgical treatment using a 10 - 0 nylon suture to successfully recanalize the occluded Xen45 Gel Stent.
CASE PRESENTATION
METHODS
A 16-year-old female patient had bilateral juvenile glaucoma for the past 5 years. Her right eye had undergone three glaucoma surgeries but failed. At a presentation to our hospital, the right eye's intraocular pressure (IOP) was 30 mmHg despite applying four different active principles. Xen45 Gel Stent implant was chosen for treatment, but six days after implantation, the IOP rose to 40 mmHg as a result of an anterior chamber tip occlusion of the Xen45 Gel Stent. Nd: YAG laser shockwave therapy was attempted but failed. The patient eventually had to return to the operating room for a revision procedure. The Xen45 Gel Stent was recanalized from the ab externo by making an L-shaped conjunctival incision at the fornix base and threading a 10 - 0 nylon suture through it. The IOP was successfully controlled in the 11-month follow-up without medication.
CONCLUSION
CONCLUSIONS
If postoperative occlusion arises after Xen45 Gel Stent implantation, surgery using 10 - 0 nylon suture to recanalize Xen45 Gel Stent should be considered as a relatively safe, effective that does not require removal of Xen45 Gel Stent.
Identifiants
pubmed: 37858210
doi: 10.1186/s12886-023-03109-7
pii: 10.1186/s12886-023-03109-7
pmc: PMC10585744
doi:
Substances chimiques
Nylons
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
418Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Eye Vis (Lond). 2020 Feb 01;7:5
pubmed: 32021876
Eye (Lond). 2019 May;33(5):761-766
pubmed: 30552422
J Glaucoma. 2018 Oct;27(10):e168-e173
pubmed: 29877970
Prog Retin Eye Res. 2009 Sep;28(5):303-28
pubmed: 19573620
J Clin Med. 2021 Mar 07;10(5):
pubmed: 33800112
J Glaucoma. 2020 Mar;29(3):155-160
pubmed: 32108690
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
J Cataract Refract Surg. 2014 Aug;40(8):1301-6
pubmed: 24943904
PLoS One. 2021 Aug 19;16(8):e0256362
pubmed: 34411152
J Clin Med. 2021 Sep 26;10(19):
pubmed: 34640435
Eye (Lond). 2018 Feb;32(2):324-332
pubmed: 28862254
Acta Ophthalmol. 2021 Jun;99(4):369-375
pubmed: 32996702
Graefes Arch Clin Exp Ophthalmol. 2020 Aug;258(8):1787-1794
pubmed: 32377823
Int Ophthalmol. 2018 Jun;38(3):1129-1134
pubmed: 28555256
Eur J Ophthalmol. 2020 Sep;30(5):1034-1041
pubmed: 31018685
Front Med (Lausanne). 2022 Feb 04;9:804847
pubmed: 35186992
J Glaucoma. 2018 Aug;27(8):739-741
pubmed: 29877971
J Glaucoma. 2017 Apr;26(4):e150-e152
pubmed: 28098579
Ophthalmol Glaucoma. 2023 Nov-Dec;6(6):580-591
pubmed: 37169174
Acta Ophthalmol. 2021 Jun;99(4):e531-e539
pubmed: 32930515
Adv Ther. 2019 Dec;36(12):3519-3529
pubmed: 31650513
J Clin Med. 2022 Aug 16;11(16):
pubmed: 36013021
Vision (Basel). 2022 Feb 09;6(1):
pubmed: 35225971
J Glaucoma. 2021 Jul 1;30(7):e338-e343
pubmed: 33826599
Medicine (Baltimore). 2021 Aug 27;100(34):e27010
pubmed: 34449471
J Curr Glaucoma Pract. 2019 Sep-Dec;13(3):113-115
pubmed: 32431478
J Ophthalmol. 2021 Jul 9;2021:2321922
pubmed: 34306742
J Glaucoma. 2019 Jun;28(6):e93-e95
pubmed: 30676411
BMC Ophthalmol. 2021 Dec 27;21(1):446
pubmed: 34961501
Eye Vis (Lond). 2019 Sep 29;6:29
pubmed: 31583261